 NEW YORK and LONDON, June 17, 2021 GLOBE NEWSWIRE -- Tiziana Life Sciences plc NASDAQ: TLSA, LSE: TILS, a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases announces that it has submitted a grant to the United Kingdom COVID Therapeutics Advisory Panel UK-CTAP to support further clinical development of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody, as an innovative Take Home approach for treatment of non-hospitalized patients with COVID-19. This is in response to a call from the UK government for proposals to study therapies that can be delivered at home and avoid hospitalization of patients. 